Phase I study to optimize the safe starting dose of weekly paclitaxel
Not Applicable
- Conditions
- head and neck cancer
- Registration Number
- JPRN-UMIN000020357
- Lead Sponsor
- Kanazawa University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with severe co-morbidity are excluded
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Starting dose to determine the individualized maximum repeatable dose
- Secondary Outcome Measures
Name Time Method